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doi:10.1016/j.jmii.2011.12.025Purpose: To assess the in vitro susceptibility of Streptococcus pneumoniae, Staphylococcus
aureus and coagulase-negative staphylococci (CoNS) ocular isolates to antibiotics, and identify
changing trends in resistance over a 10-year period.
Methods: All isolates from ocular infections collected between 2000 and 2009 were prospec-
tively tested against several antibiotics in vitro. S. pneumoniae isolates (n Z 93) were tested
against 20 and S. aureus (n Z 120) and CoNS (n Z 214) against 19 antibiotics. To identify
changes in susceptibility patterns, we compared results from 2000e2004 with those from
2005e2009. We also compared the antibiotic susceptibilities against aminoglycosides and qui-
nolones between methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus
(MSSA) isolates.
Results: All S. pneumoniae isolates were susceptible to quinolones, and 99% were susceptible
to chloramphenicol. Regarding S. aureus, we noted a significant increase in resistance against
penicillin in recent years (p Z 0.016). Over 90% of S. aureus isolates were susceptible to qui-
nolones and aminoglycosides. MRSA isolates were more resistant to ciprofloxacin and ofloxacin
than MSSA isolates were (p Z 0.016). Concerning CoNS, a significant increase in susceptibility
to amikacin was noted in the second study period (p Z 0.01).of Clinical Microbiology, Parasitology, Zoonoses and Geographical Medicine, University Hospital of
reece.
(S. Maraki).
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keratitis due to Gram-positive cocci in our region.
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The eye can be affected by a wide spectrum of infections,
some of which are vision-threatening. Adequate preventive
measures, knowledge of the most common bacterial path-
ogens and their antibiotic susceptibility patterns in a given
locale, and therapy with suitable antibiotics, constitute the
cornerstones for the successful management of ocular
infections.1
Streptococcus pneumoniae, Staphylococcus aureus and
coagulase-negative staphylococci (CoNS) are important
ophthalmic pathogens implicated frequently in ocular
infections. In most series published to date, these Gram-
positive cocci are the most prevalent bacterial pathogens
implicated in cases of bacterial conjunctivitis and keratitis,
along with Pseudomonas aeruginosa and Moraxella spp.2
Distinction of ocular isolates into those that cause
bacterial conjunctivitis versus keratitis is important.
Bacterial conjunctivitis is considered a mild and self-
limited infection. In this infection, although topical anti-
biotics are associated with higher rates of early clinical
remission, their benefit is minimal at later time points.3 On
the other hand, keratitis may be vision-threatening without
prompt and adequate treatment. Moreover, bacterial
isolates from cases of keratitis are frequently more resis-
tant to antibiotics, suggesting that virulence may correlate
with increased antibacterial resistance.4
The goal of the present study was to describe the in vitro
antibiotic susceptibility patterns of S. pneumoniae,
S. aureus and CoNS ophthalmic isolates derived from chil-
dren (patients aged  14 years) and adults with bacterial
conjunctivitis and keratitis that were cared for over a 10-
year period in the University Hospital of Heraklion, the
only tertiary hospital in the island of Crete, Greece.Materials and methods
We prospectively tested against several antibiotics all
ophthalmic isolates of S. pneumoniae, S. aureus and CoNS
that were recovered from patients with bacterial
conjunctivitis and keratitis and cared for in the University
Hospital of Heraklion over the period January
2000eDecember 2009. One bacterial isolate was tested per
patient. Our study met the ethical guidelines of the
Declaration of Helsinki, and adhered to the legal require-
ments of the University Hospital of Heraklion regarding
institutional review board approval for in vitro investiga-
tions of antibiotic susceptibilities of human isolates. For
epidemiological reasons, we did not limit the susceptibility
testing only to antibiotics administered topically for ocular
infections. We also used antibiotics that are administered
parenterally, since antibacterial resistance to oneantibiotic frequently heralds the development of resistance
to other antibacterials. For example, the emergence of
resistance to b-lactams among S. aureus isolates is
frequently associated with resistance to quinolones and
even glycopeptides.5
The antibiotics that were tested against S. pneumoniae,
S. aureus and CoNS ophthalmic isolates are shown in Table
1. The ophthalmic specimens were collected with sterile
applicator swabs and transported to the laboratory within
<2 hours after collection, along with written documenta-
tion about the type of underlying ocular infection necessi-
tating specimen collection.
Identification of S. pneumoniae was based on colony and
microscopic morphology, hemolytic activity on sheep blood
agar medium, catalase test, optochin susceptibility, bile
solubility, and biochemical profile using the API 20 Strep
System (BioMe´rieux, Marcy l’ Etoile, France). S. aureus and
CoNS were identified on the basis of colony morphology,
Gram stain, catalase and coagulase test, and the API 20
Staph System (BioMe´rieux). Antimicrobial susceptibility
tests were performed by employing the disk diffusion
method and the results were interpreted according to the
2010 Clinical and Laboratory Standards Institute criteria.6
Intermediate isolates were grouped along with resistant
isolates. For S. pneumoniae isolates, minimum inhibitory
concentrations (MICs) were determined for penicillin G,
cefuroxime, cefotaxime, ceftriaxone, erythromycin and
clindamycin using the E-test method (AB Biodisk, Solna,
Sweden).
To test for differences in the antibiotic susceptibility
patterns between the earlier and later study years for
a given antibiotic, we compared the resistance profiles of
ophthalmic isolates from 2000e2004 with those from
2005e2009. Finally, we compared the quinolone suscepti-
bility patterns between ophthalmic and non-ophthalmic
isolates of S. aureus, that is, isolates obtained from all
other body sites for the whole 10-year study period.
Statistical analysis was conducted by ManneWhitney,
Fisher’s exact and c2 tests, as appropriate. Statistical
significance was set at p < 0.05 (two-tailed). All analyses
were performed with Graphpad Prism version 4 (GraphPad
Software, San Diego, CA, USA).
Results
Overall, 427 ocular isolates of the Gram-positive cocci of
interest were recovered during the 10-year study period
from patients with bacterial conjunctivitis (n Z 340) and
keratitis (n Z 87). These included 214 (50.1%) isolates of
CoNS, 120 (28.1%) of S. aureus and 93 (21.8%) of
S. pneumoniae. During the study period, we also isolated
278 other ophthalmic pathogens (130 during 2000e2004 and
148 during 2005e2009). These belonged to 37 different
Table 1 Resistance profiles of 93 Streptococcus pneumoniae, 120 Staphylococcus aureus and 214 CoNS isolates from patients
with keratitis and conjuctivitis
2000e2004 2005e2009 p value
Resistant Sensitive Resistant Sensitive
S. pneumoniae
01 Penicillin 10 (23.8%) 32 (76.2%) 13 (25.5%) 38 (74.5%) 1
02 Cefuroxime 7 (16.7%) 35 (83.3%) 6 (11.8%) 45 (88.2%) 0.56
03 Cefotaxime 2 (4.8%) 40 (95.2%) 1 (2%) 50 (98%) 0.59
04 Ceftriaxone 1 (2.4%) 41 (97.6%) 1 (2%) 50 (98%) 1
05 Cefepime 4 (9.5%) 38 (90.5%) 3 (5.9%) 48 (94.1%) 0.70
06 Imipenem 6 (14.3%) 36 (85.7%) 4 (7.8%) 47 (92.2%) 0.34
07 Meropenem 2 (4.8%) 40 (95.2%) 0 (0%) 51 (100%) 0.20
08 Erythromycin 13 (31%) 29 (69%) 16 (31.4%) 35 (68.6%) 1
09 Clarithromycin 13 (31%) 29 (69%) 16 (31.4%) 35 (68.6%) 1
10 Clindamycin 4 (9.5%) 38 (90.5%) 7 (13.7%) 44 (86.3%) 0.75
11 Roxithromycin 13 (31%) 29 (69%) 16 (31.4%) 35 (68.6%) 1
12 Ciprofloxacin 0 (0%) 42 (100%) 0 (0%) 51 (100%) d
13 Ofloxacin 0 (0%) 42 (100%) 0 (0%) 51 (100%) d
14 Levofloxacin 0 (0%) 42 (100%) 0 (0%) 51 (100%) d
15 Moxifloxacin 0 (0%) 42 (100%) 0 (0%) 51 (100%) d
16 Gatifloxacin 0 (0%) 42 (100%) 0 (0%) 51 (100%) d
17 Chlorampenicol 1 (2.4%) 41 (97.6%) 0 (0%) 51 (100%) 0.45
18 Tetracycline 13 (31%) 29 (69%) 9 (17.6%) 42 (82.4%) 0.15
19 TMPeSMX 12 (28.6%) 30 (71.4%) 12 (23.5%) 39 (76.5%) 0.64
20 Vancomycin 0 (0%) 42 (100%) 0 (0%) 51 (100%) d
S. aureus
01 Penicillin 37 (72.5%) 14 (27.5%) 62 (89.9%) 7 (10.1%) 0.016
02 Oxacillin 16 (31.4%) 35 (68.6%) 28 (40.6%) 41 (59.4%) 0.34
03 Cephalothin 16 (31.4%) 35 (68.6%) 29 (42%) 40 (58%) 0.26
04 Gentamicin 5 (9.8%) 46 (90.2%) 1 (1.4%) 68 (98.6%) 0.08
05 Tobramycin 15 (29.4%) 36 (70.6%) 10 (14.5%) 59 (85.5%) 0.068
06 Amikacin 15 (29.4%) 36 (70.6%) 10 (14.5%) 59 (85.5%) 0.068
07 Netilmicin 5 (9.8%) 46 (90.2%) 1 (1.4%) 68 (98.6%) 0.08
08 Chloramphenicol 13 (25.5%) 38 (74.5%) 13 (18.8%) 56 (81.2%) 0.50
09 Tetracycline 9 (17.6%) 42 (82.4%) 9 (13%) 60 (87%) 0.60
10 Erythromycin 11 (21.6%) 40 (78.4%) 19 (27.5%) 50 (72.5%) 0.53
11 Clindamycin 3 (5.9%) 48 (94.1%) 8 (11.6%) 61 (88.4%) 0.35
12 Ciprofloxacin 2 (3.9%) 49 (96.1%) 2 (2.9%) 67 (97.1%) 1
13 Ofloxacin 2 (3.9%) 49 (96.1%) 2 (2.9%) 67 (97.1%) 1
14 Levofloxacin d d 1 (2.7%) 36 (97.3%) d
15 Moxifloxacin d d 1 (2.7%) 36 (97.3%) d
16 TMPeSMX 4 (7.8%) 47 (92.2%) 0 (0%) 69 (100%) 0.03
17 Rifampicin 1 (2%) 50 (98%) 0 (0%) 69 (100%) 0.43
18 Fucidin 9 (17.6%) 42 (82.4%) 5 (7.2%) 64 (92.8%) 0.09
19 Fosfomycin 1 (2%) 50 (98%) 0 (0%) 69 (100%) 0.43
20 Vancomycin 0 (0%) 51 (100%) 0 (0%) 69 (100%) d
21 Teicoplanin 0 (0%) 51 (100%) 0 0%) 69 (100%)
CoNS
01 Penicillin 97 (89%) 12 (11%) 93 (88.6%) 12 (11.4%) 1
02 Oxacillin 38 (34.9%) 71 (65.1%) 50 (47.6%) 55 (52.4%) 0.07
03 Cephalothin 38 (34.9%) 71 (65.1%) 50 (47.6%) 55 (52.4%) 0.07
04 Gentamicin 26 (23.9%) 83 (76.1%) 20 (19%) 85 (81%) 0.41
05 Tobramycin 62 (56.9%) 47 (43.1) 46 (43.8%) 59 (56.2) 0.07
06 Amikacin 61 (56%) 48 (44%) 41 (39%) 64 (61%) 0.01
07 Netilmicin 26 (23.9%) 83 (76.1%) 18 (17.1%) 87 (82.9) 0.24
08 Chloramphenicol 20 (18.3%) 89 (81.7%) 18 (17.1%) 87 (82.9) 0.86
09 Tetracycline 18 (16.5%) 91 (83.5) 26 (24.8%) 79 (75.2%) 0.17
10 Erythromycin 46 (42.2%) 63 (57.8) 47 (44.8%) 58 (55.2%) 0.78
(continued on next page)
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Table 1 (continued )
2000e2004 2005e2009 p value
Resistant Sensitive Resistant Sensitive
11 Clindamycin 30 (27.5%) 79 (72.5%) 34 (32.4%) 71 (67.6%) 0.45
12 Ciprofloxacin 7 (6.4%) 102 (93.6%) 10 (9.5%) 95 (90.5%) 0.45
13 Ofloxacin 6 (5.5%) 103 (94.5%) 9 (8.6%) 96 (91.4) 0.43
14 TMPeSMX 9 (8.3%) 100 (91.7) 12 (11.4%) 93 (88.6%) 0.49
15 Rifampicin 3 (2.8%) 106 (97.2%) 17 (16.2%) 88 (83.8%) 0.0007
16 Fucidic acid 63 (57.8%) 46 (42.2%) 60 (57.1%) 45 (42.9%) 1
17 Fosfomycin 13 (11.9) 96 (88.1%) 12 (11.4%) 93 (88.6%) 1
18 Vancomycin 0 (0%) 109 (100%) 0 (0%) 105 (100%) d
19 Teicoplanin 0 (0%) 109 (100%) 0 (0%) 105 (100%) d
CoNS Z coagulase-negative staphylococci; TMPeSMX Z trimethoprimesulfamethoxazole.
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Gram-positive and the remaining 220 (79%) were Gram-
negative, with no significant difference between the two
study periods. The same was true for the prevalence of the
studied ocular pathogens of interest within all the
ophthalmic bacterial pathogens of the 10-year surveillance
period (data not shown). The most prevalent other patho-
gens were Haemophilus influenzae and P. aeruginosa that
were responsible for 46% of the positive ophthalmic
cultures for pathogens other than S. aureus, S. pneumoniae
and CoNS.
Approximately 53% (226/427) of the study isolates came
from the day clinic of the Department of Ophthalmology,
whereas the remaining were collected in one of the several
departments and/or clinics of the University Hospital of
Heraklion.
Demographic data of patients with bacterial conjuncti-
vitis and keratitis are shown in Table 2. The distribution of
patients into children and adults differed significantly by
ophthalmic pathogen (p Z 0.0004), whereas no significant
difference in the distribution of the three ophthalmic
pathogens was seen by sex (p Z 0.61).
Among the 93 isolates of S. pneumoniae, 42 were
collected during the years 2000e2004 and 51 during
2005e2009. Sixty-eight of these isolates (73.1%) came from
patients who suffered from conjunctivitis and the remain-
ing 25 (26.9%) from patients with keratitis. Comparing the
antibiotic susceptibility patterns of S. pneumoniae isolates
from the two periods, no statistically significant change was
noted for any of the 20 antimicrobials tested (Table 1). All
93 ophthalmic S. pneumoniae isolates were susceptible to
all five quinolones tested, that is, ciprofloxacin, ofloxacin,
levofloxacin, moxifloxacin and gatifloxacin. Moreover, 99%
of S. pneumoniae isolates were susceptible to chloram-
phenicol. Comparing the antibiotic susceptibility patternsTable 2 Demographic data of patients with bacterial conjuncti
Pathogen Sex, n (%)
Streptococcus pneumoniae M: 46 (49.4%) F: 47 (50.6%)
Staphylococcus aureus M: 59 (49.2%) F: 61 (50.8%)
CoNS M: 123 (57.5%) F: 91 (42.5%
Total M: 228 (53.4%) F: 199 (46.6
CoNS Z coagulase-negative staphylococci; F Z female; M Z male.between S. pneumoniae conjunctivitis versus keratitis
isolates, there was no significant difference for any of the
20 antibiotics tested (data not shown).
Regarding S. aureus, 51 and 69 ophthalmic isolates of this
pathogenwere recovered during 2000e2004 and 2005e2009,
respectively. Eighty-three of these isolates (69.2%) came
from patients with conjunctivitis and the remaining 37
(30.8%) from patients with keratitis. Comparing the antibi-
otic susceptibility patterns between the two study periods,
we noted a significant increase in resistance against peni-
cillin in recent years, along with a significant decrease
in resistance against trimethoprimesulfamethoxazole
(Table 1). Interestingly, methicillin-resistant S. aureus
(MRSA) was not significantly more common during the more
recent study years, as we had hypothesized. As seen from
the data in Table 1, there was a trend for decreased resis-
tance of S. aureus against aminoglycosides (gentamicin,
tobramycin, amikacin and netilmicin) in recent years, which
did not, however, reach statistical significance. Comparing
the antibiotic susceptibility patterns between conjunctivitis
and keratitis isolates, there was no significant difference for
any of the 19 antibiotics tested (data not shown).
We also compared the susceptibilities to aminoglyco-
sides, quinolones and chloramphenicol of MRSA (n Z 44)
and methicillin-sensitive S. aureus (MSSA; nZ 76) isolates.
MRSA isolates were more resistant to ciprofloxacin and
ofloxacin, whereas no differences in susceptibility were
seen for any of the four aminoglycosides or for chloram-
phenicol (Table 3).
Table 4 shows the comparison of quinolone susceptibility
patterns between ophthalmic and nonophthalmic isolates
of S. pneumoniae and S. aureus (2000e2009). As seen from
these data and Table 1, ofloxacin susceptibility was not
tested for nonophthalmic isolates of S. pneumoniae,
whereas levofloxacin and moxifloxacin susceptibility datavitis and keratitis (n Z 427)
Age (median, range) Children  14 yr
7 yr (1 moe86 yr) 52/93 (55.9%)
25.5 yr (1 moe88 yr) 49/120 (40.8%)
) 32 yr (1 moe89 yr) 68/214 (31.8%)
%) 29.8 yr (1 moe89 yr) 169/427 (39.6%)
Table 3 Comparison of antibiotic susceptibilities to aminoglycosides and quinolones of MRSA and MSSA isolates
2000e2009 MRSA (n Z 44) MSSA (n Z 76) p value
Resistant Sensitive Resistant Sensitive
Gentamicin 1 43 5 71 0.41
Tobramycin 10 34 14 62 0.64
Amikacin 10 34 14 62 0.64
Netilmicin 1 43 5 71 0.41
Ciprofloxacin 4 40 0 76 0.016
Ofloxacin 4 40 0 76 0.016
Chloramphenicol 13 31 13 63 0.167
MRSA Z methicillin-resistant Staphylococcus aureus; MSSA Z methicillin-sensitive Staphylococcus aureus.
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2005e2009.
Regarding CoNS, 109 isolates were recovered during
2000e2004, and 105 during 2005e2009 from 155 (72.4%)
patients with conjunctivitis and 59 patients (27.6%) with
keratitis. These isolates belonged to the following nine
species: 176 Staphylococcus epidermidis, 17 Staphyloccocus
hominis, seven Staphylococcus haemolyticus, five Staph-
ylocccus capitis, three Staphylococcus warneri, two Staph-
yloccocus xylosus, two Staphylococcus lungdunensis, one
Staphylococcus simulans, and one Staphylococcus cohnii.
Comparing the antibiotic susceptibility patterns between
the two study periods, we noted a significant decrease in
resistance against amikacin in 2005e2009, along with
a significant increase in resistance against rifampicin (Table
1). Moreover, there was a trend for decreased resistance
against tobramycin and a trend for increased resistance to
oxacillin and cephalothin in the second study period. No
CoNS isolates were resistant to glycopeptides (vancomycin
and teicoplanin). Comparing the antibiotic susceptibility
patterns between CoNS isolates from conjunctivitis versus
keratitis cases, there was no significant difference for any of
the tested antibiotics (data not shown).
Discussion
The main finding of this study is that second-generation
quinolones (ciprofloxacin and ofloxacin), and newer third-
(levofloxacin) and fourth-generation (moxifloxacin andTable 4 Comparison of quinolone susceptibility patterns betwe




01 Ciprofloxacin 0 (0%) 93 (100%)
02 Ofloxacin 0 (0%) 93 (100%)
03 Levofloxacin 0 (0%) 93 (100%)
04 Moxifloxacin 0 (0%) 93 (100%)
S. aureus
01 Ciprofloxacin 4 (3.4%) 116 (96.6%
02 Ofloxacin 4 (3.4%) 116 (96.6%
03 Levofloxacin 1 (2.7%) 36 (97.3%)
04 Moxifloxacin 1 (2.7%) 36 (97.3%)gatifloxacin) fluoroquinolones appear to be very effective
in vitro against ophthalmic isolates of S. pneumoniae,
because all isolates were susceptible to these antibiotics.
Moreover, quinolone susceptibility was similar for
ophthalmic and nonophthalmic isolates of S. pneumoniae.
Chloramphenicol, an old, cheap, and widely used antibiotic
for ocular infections was also highly effective, and 99% of the
S. pneumoniae ophthalmic isolates were susceptible to it.
A second finding of our studywas that both quinolones and
aminoglycosides appeared to be effective (> 90% suscepti-
bility rates) against ophthalmic isolates of S. aureus. This is
important because corneal perforations can occur within
<24 hours in the presence of particularly invasive bacterial
pathogens, such as S. aureus, and topical ocular antibiotic
solutions of fluoroquinolones and aminoglycosides appear to
be the drugs of choice in this case.
We did not see a significant increase in recent years of
ocular MRSA isolates, like the increase we have seen with
this pathogen in other body sites at our institution.
Although we did not see high rates of resistance of S. aureus
isolates to quinolones, MRSA isolates were significantly
more resistant to these antibiotics compared to MSSA
isolates. In the Ocular Tracking Resistance in U.S. Today
study, MSSA susceptibility for the fluoroquinolones was
79.9e81.1% and MRSA susceptibility was only 15.2%.7 Elsahn
et al have determined the in vitro susceptibility of 40
ophthalmic isolates of S. aureus including 21 MRSA isolates,
and found that 90% of MRSA isolates were resistant to
fourth-generation fluoroquinolones.8 Therefore, in areasen ophthalmic and nonophthalmic isolates of Streptococcus
Nonophthalmic p value
Resistant Sensitive
4 (1.1%) 387 (98.9%) 1
d d d
1 (0.3%) 390 (99.7%) 1
1 (0.3%) 390 (99.7%) 1
) 407 (15.9%) 2160 (84.1%) 0.0001
) 408 (15.9%) 2160 (84.1%) 0.0001
206 (13.1%) 1367 (86.9%) 0.08
165 (10.2%) 1467 (89.8%) 0.17
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consider alternative therapies to fluoroquinolones, if MRSA
is a likely ophthalmic pathogen. The In Vitro Antibiotic
Testing Group has studied the antibiotic susceptibilities of
1291 ocular isolates in North and South America by both
disk- and broth-dilution methods. The fluoroquinolones
tested (ciprofloxacin, ofloxacin and norfloxacin) had higher
overall in vitro efficacy than the other antibiotics tested.
Among them, ofloxacin had the highest in vitro efficacy
against Gram-positive organisms.9
In our study, we saw an increase in resistance of
S. aureus to aminoglycosides (gentamicin, tobramycin,
amikacin and netilmicin) in recent years, which did not,
however, reach statistical significance. However, S. aureus
isolates showed >96% susceptibility to quinolones. More-
over, S. aureus ocular isolates were more susceptible to
quinolones compared to nonophthalmic isolates (Table 4).
Emerging fluoroquinolone resistance is an issue in several
parts of the world.10 Goldstein et al have reviewed all cases
of bacterial keratitis presenting to the Eye and Ear Institute
in Pittsburgh from 1993 to 1997, and showed significantly
increasing resistance rates of S. aureus keratitis isolates to
ciprofloxacin, from 5.8% in 1993 to 35% in 1997.11 In the
same study, Streptococcus spp. and CoNS also showed
significant resistance to fluoroquinolones, but no change in
resistance over the years.
Marangon et al from the Bascom Palmer Eye Institute in
Miami, USA, have shown that ciprofloxacin and levofloxacin
resistance among MSSA corneal and conjunctival isolates is
increasing.12 More specifically, ciprofloxacin resistance
among corneal and conjunctival S. aureus isolates during
1990e1995 was 8% (range: 3e11%), whereas the rate of
resistance during 1996e2001 was 20.7%. Baseline cipro-
floxacin resistance for MSSA isolates was 2% versus 55.8% for
MRSA isolates. The levofloxacin-resistance rate for MSSA
was 4.7% versus 11.9% for ciprofloxacin. In MRSA isolates,
a significantly higher resistance rate was found for cipro-
floxacin (95.7%) versus levofloxacin (82.1%).12 The claim
that fourth-generation fluoroquinolones are statistically
more potent than second-generation fluoroquinolones
against Gram-positive bacteria has been shown in other
studies as well.13 However, due to pharmacokinetic
differences, not all fourth-generation fluoroquinolones are
similar in the way that they eradicate bacterial ophthalmic
pathogens. For example, the ophthalmic solution of 0.3%
gatifloxacin eradicates bacteria implicated in post-
operative ocular infections substantially faster than the
ophthalmic solution of 0.5% moxifloxacin.14 Regarding
moxifloxacin, it has been shown to kill bacteria more
rapidly than nonfluoroquinolone topical ocular antibi-
otics.15 Scoper has reviewed studies that investigated the
therapeutic potential of levofloxacin and has compared it
to that of existing fourth-generation fluoroquinolones.16
Eight eligible studies published between 2002 and 2008
have been reviewed. The five in vitro studies have
demonstrated that moxifloxacin and gatifloxacin are
statistically more potent than levofloxacin against Gram-
positive organisms. In vivo animal models testing moxi-
floxacin or gatifloxacin against 0.5% levofloxacin have
demonstrated that fourth generation agents are superior to
levofloxacin for prophylaxis of infections due to Gram-
positive bacteria.We saw an increase in resistance of S. aureus against
penicillin and a decrease in resistance of this pathogen
against trimethoprimesulfamethoxazole in recent years.
Spread of penicillin resistance among S. pneumoniae ocular
strains has been well known for several years. In a study
from India, among the 25 isolates of S. pneumoniae derived
from 617 ophthalmic specimens, only four (16%) exhibited
intermediate resistance to penicillin.17 By contrast, among
the 25 non-typable ocular isolates of S. pneumoniae tested
by Kojima et al in 2006, 40% were intermediately resistant
to penicillin (MIC: 0.1e1 mg/mL).18
With regard to chloramphenicol, this agent has been
shown to be very effective against ocular infections due to
Gram-positive bacteria. In the study by Schaefer et al, the
sensitivity rate of Gram-positive strains to chloramphenicol
was 98%.1 Fukuda et al have found that chloramphenicol
sensitivity of MRSA isolates from bacterial conjunctivitis
cases was 98%.19 Moreover, in the same study, the in vivo
efficacy of chloramphenicol eye drops in the treatment of
MRSA conjunctivitis was 81%. In our study, 99% of the
S. pneumoniae isolates, and 79% of the S. aureus isolates
were susceptible to this agent in vitro.
Regarding CoNS, 92% of the isolates were susceptible to
ciprofloxacin and 93% to ofloxacin. In the study by Elsahn
et al, 65% of the 29 methicillin-resistant CoNS were
susceptible to the fourth generation fluoroquinolones and
gentamicin.8 We saw a significant increase in susceptibility
of CoNS to aminoglycosides, predominantly amikacin and to
a lesser degree tobramycin, over the period 2005e2009;
probably due to the decreased use of topical aminoglyco-
sides in favor of quinolones for ophthalmic infections in
recent years. Chlorampenicol was effective in vitro against
82% (176/214) of CoNS isolates; a finding similar to previous
studies. In a study by Chalita et al, chloramphenicol was
effective against 87% of the corneal and 88.5% of the
conjunctival isolates of CoNS.20 Regarding cephalothin,
41.1% (88/214) of our CoNS isolates were resistant to this
first-generation cephalosporin; a similar percentage to S.
aureus (45/120 or 37.5%). In a study from Australia, 80% of
Gram-positive isolates from patients with keratitis over a 5-
year period were susceptible to cephalothin.21 Hence, the
antibiotic susceptibility patterns of CoNS show substantial
geographic variability that should be taken into account
when choosing antibiotic therapy for ophthalmic infections.
The overall in vitro susceptibility rate of the three
Gram-positive organisms of interest to ciprofloxacin was
high at 95.1% (406/427) with the low resistance being
limited to S. aureus (3.3% or 4/120) and CoNS (7.9% or 17/
214) isolates alone. Among 485 cases of bacterial keratitis
referred to the Massachusetts Eye and Ear Infirmary over
two consecutive annual 10-month periods in 1999 and 2000,
the cumulative resistance of Gram-positive isolates to
ciprofloxacin was 12% and 22%, respectively; figures
substantially higher than ours.22
Our study was limited by the lack of clinical follow-up.
Thus, we did not capture data for the type of antibiotic
chosen by the treating physicians, the possible modifications
made in the initial antibiotic regimens based on the results
of the in vitro antibiotic susceptibility testing, and most
importantly, the clinical outcomes of the patients treated.
In conclusion, the in vitro antibiotic susceptibilities of
S. pneumoniae and to a lesser extend of S. aureus and of
Susceptibility of Gram-positive ocular isolates 47CoNS have not changed substantially in our region over the
past decade. Quinolones appear to be an excellent treat-
ment option for cases of bacterial conjunctivitis and
keratitis in Crete, because they cover almost all ocular
S. pneumoniae and S. aureus ophthalmic isolates, and >90%
of CoNS isolates. Although MRSA ocular isolates are more
resistant to quinolones compared to MSSA isolates, the
overall low rates of resistance to quinolones make these
agents the antibiotics of choice in cases of bacterial
conjunctivitis and keratitis. Additionally, chloramphenicol
is an excellent treatment option for ocular infections due to
S. pneumoniae. Continued surveillance of the antibiotic
susceptibility patterns of bacterial pathogens implicated in
ocular infections in our region will provide valuable data to
ophthalmologists and other clinicians for the selection and
use of the most appropriate empirical antimicrobial agents.References
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